title: Prulifloxacin as a trigger of myasthenia gravis.
abstract: Fluoroquinolones has been rarely associated with exacerbation of myasthenia gravis (MG). We present a case of MG following a treatment with prulifloxacin, a new broad-spectrum oral fluoroquinolone. Fluoroquinolones of any generation may interfere with neuromuscular transmission and should be avoided in patients with MG.
authors.affiliation: Department of Pharmacology Giorgio Segre, University of Siena, Siena, Italy. marcorss@alice.it
authors.forename: Marco
authors.initials: M
authors.lastname: Rossi
authors.forename: Gaia
authors.initials: G
authors.lastname: Lusini
authors.forename: Alessia
authors.initials: A
authors.lastname: Biasella
authors.forename: Riccardo
authors.initials: R
authors.lastname: Mazzocchio
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003556:Cystitis / Q000188:drug therapy; D004148:Dioxolanes / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009157:Myasthenia Gravis / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; C074191:prulifloxacin